Summary The clinical course of breast cancer was related to degree of anaplasia (DA) and steroid receptor (SR) content of primary tumours in 743 patients (pts) with clinical recurrence, initially enrolled in the DBCG-77 protocols. The oestrogen receptor (ER) and the progesterone receptor (PgR) content was known in 110 and 67 pts. The recurrence-free interval, survival after recurrence, and the overall survival were all prolonged in patients with well differentiated tumours or with high SR content.
In general, breast cancer is a subclinical disseminated disease at the time of initial diagnosis, and in most patients disease is expected to recur. Although the ultimate outcome of the disease can thus be predicted for most patients, there are considerable variations in length of survival (Brinkley & Haybittle, 1975) .
Subsets of patients with breast cancer who have approximately the same expected survival time can be identified by means of various features of the patients or their primary tumours (i.e., prognostic factors). Generally, such factors are considered to reflect metastatic potential or growth rate. However, supplementary interpretations of these prognostic factors may reveal that their impact on survival is mediated through differences in extent and/or anatomical location of recurrent disease. According to this concept, different prognostic characteristics may predict different metastatic patterns. Dissimilarities in both the degree of anaplasia (DA) and steroid receptor (SR) content of the primary tumour probably influence prognosis by differences in growth rate. Thus, less differentiated tumours and tumours with a low receptor content have a higher growth rate (Meyer et al., 1986; Adami et al., 1985) and, consequently, a shorter survival (Schnuerch et al., 1985; Heuson et al., 1977) than higher differentiated and receptor rich tumours. However, variations in prognosis with DA and SR content may also reflect differences in the pattern of spread. The present study was undertaken to examine whether such relationships exist.
Materials and methods
Criteria of selection All patients had initially operable breast cancer and participated in the 77 protocols of the Danish Breast Cancer Cooperative Group (DBCG) study of primary treatment and follow up . They were all followed at one of the participating oncological centres or at the regional Correspondence: C. Kamby The primary treatment was total mastectomy with partial axillary dissection. Patients were divided into a high and a low risk group: Low risk patients had tumours < 5 cm in diameter, no positive nodes, and no invasion of skin or fascia. These patients received no further therapy following mastectomy. The high risk patients had tumours >5cm in diameter and/or positive lymph nodes and/or skin or fascial invasion. These patients received postoperative radiotherapy to the chest wall, the axillary and periclavicular areas equivalent to 1335 rets, and were further randomized to different forms of systemic adjuvant treatments as described in detail elsewhere Kamby et al., 1988) .
All patients were seen for physical examination every 3 months until 18 months after mastectomy, and every 6 months thereafter. Chest X-rays, bone scintigraphy, and blood chemistry were carried out every 6 months for one year. Thereafter, chest X-rays were repeated once a year for another 4 years. Abnormal bone scintigram required bone X-ray survey. (Scarff, Br. J. Cancer (1988 ), 58, 480-486 1968 . The ductal carcinomas NOS were classified as well (DA = I), medium (DA = II), and poorly (DA = III) differentiated, according to the grading system of Bloom & Richardson (1957) , using the following histologic factors: (1) tubule formation; (2) pleomorphism, and (3) mitotic nuclei. proportions, since the period of observation was shorter for the SR determined subgroup of patients (cf. above).
Comparisons of the frequencies of metastases were performed by the Chi-square or the rank t-test (Mann-Whitney rank sum test) for ordered categories (Bartolucci, 1984; Bross, 1954) . The Mantel-Haenszel chi-square statistics extended for stratified data was used in order to control for the possible confounding effect of stage, DA, and SR (Kleinbaum et al., 1982) . Actuarial life table analyses have been performed on all data concerning RFI, OS, SAR, and progression time. The log rank test was used to evaluate differences between survival curves (Peto et al., 1977) . A two-tailed P value of <0.05 was considered significant.
Results

Patient characteristics
The median time (range) of follow up from initial diagnosis was 4.9 years (2.0-7.0), and the median (range) period of observation after recurrence was 3.6 years (0.8-6.4). A total of 863 patients with clinical recurrence met the criteria of selection. Table I shows the distribution of these patients according to menopausal status, primary stage, and type of systemic adjuvant therapy.
Degree of anaplasia
The DA of the primary tumour was known in 743 patients (86%). Of these, 133 patients (18%) had grade I, 431 patients (58%) had grade II, and 179 patients (24%) had grade III tumours. Fourteen percent of the 863 patients with clinical recurrence could not be graded, because their tumours were not ductal.
Survival Patients with low differentiated tumours had a shorter OS than patients with higher differentiated tumours. The reduction in OS comprised both a reduction of RFI (P=0.0001) and SAR (P=0.0001) of stage II patients, whereas only RFI was effected in stage I patients (P=0.02). The actuarial three year survival rates according to DA I, II, and III were 93%, 89%, and 89% in patients with stage I (P=0.06), and 91%, 76%, and 63% in stage II patients (P=0.0001). Grade III tumours occurred more often in patients with stage II disease than they did in stage I patients (P<0.0001; rank t-test).
Metastatic pattern Most patients recurred initially in a single site. There were no differences in the number of metastatic sites between groups of patients with tumours of different DA's (Table II) . The most common site of first metastasis was bone (36% of all patients with recurrence), followed by recurrence in lung (24%) and local skin (22%). The incidence of visceral metastases was increasing with increasing DA, whereas the distribution of soft tissue and bone metastases was unassociated with DA, both at the time of first recurrence ( Figure 1 ) and at the time of evaluation The progression time (I.e., interval between first and subsequent distant metastases) was shorter for patients with grade II and III tumours than for patients with grade I tumours. Thus, although the differences are not statistically significant, more than 40% of the grade II and III patients developed multiple distant metastases within 3 years compared to 21% of the grade I patients. There were no differences in type of adjuvant treatment and treatment of advanced disease among patients with different DA (P=0.25) (Table IV) .
Steroid receptor data The ER content of the primary tumour was determined in 110 of the 863 patients; 35 patients (32%) had <10fmolmg-1, 44 patients (40%) had 10-99fmolmg-1, and 31 patients (28%) had .100fmol ERmg-1 cytosol protein. The PgR content was measured in 67 of the patients with recurrence; 29 patients (43%) had <10fmolmg-1, 21 patients (31%) had 10-99fmolmg-1, and 17 patients (25%) had .100 fmol PgR mg-1 cytosol protein. The anatomical distribution of metastases at the time of first recurrence is presented according to SR status in Figures 3 and 4 . There was a propensity for receptor positive tumours to recur in bone (P <0.05), while ER negative tumours more often recurred in lung, liver, and brain. When the ER data were analyzed semiquantitatively, it was found that while the incidence of contralateral breast tumours increased with increasing ER concentrations, visceral metastases occurred more often among patients with low ER content (Table V) . These differences were also found at the time of evaluation. The anatomical distribution of metastases according to PgR content was in agreement with the ER data except for contralateral breast and lung (small numbers). Thus, although the numbers are small, the data show a tendency for tumours with high PgR content to recur in bone, and with low PgR content to recur in the liver. The 
Brain 2 purpose to elucidate whether the prognostic effect of these features also reflects different clinical manifestations of the disease, since differences such as metastatic extent and progression rate may reflect basic biological tumour characteristics. Moreover, a connection between a prognostic variable and a certain metastatic pattern and/or growth rate could suggest a specific mechanism of action of the prognostic factor. According to this working hypothesis, which is outlined in Figure 5 , the finding of a uniform metastatic pattern and growth rate between prognostic strata indicates that differences in tumour age may play a major role (i.e., chronological prognostic factors).
Histological grading techniques involve subjectivity, and only between 60% and 77% of the results can be reproduced (Stenkvist et al., 1979) . Data concerning DA were extracted from the DBCG data base. Tumour grading was not reviewed for the present study, and this may introduce statistical 'noise'. However, from a statistical point of view, random inaccuracies in the measurement of a variable can mask an existing correlation but cannot create an artefactual relationship. Moreover, the result of tumour grading from the DBCG-77 programme has prognostic significance Rank et al., 1987) . Thus, despite the multi-institutional basis of the material, the classification according to DA may reflect division of tumours in biological entities. While data on tumour grade are available for 84% of the patients with recurrence, receptor data are available for only 15% of the patients. Although patients with and without receptor measurements were without differences with regard to the occurrence of important prognostic factors, the results of the anafysis of grade would appear to be more reliable than those for receptor status.
The study confirms that survival from initial diagnosis is related to both the DA and the SR content of the primary tumour (Schnuerch et al., 1985; Heuson et al., 1977) . The reduced survival of patients with either low differentiated or receptor poor tumours applied to a shortening of both RFI and SAR compared to patients with either high differentiated or receptor rich tumours. This indicates that differences in the status of either DA or SR reflect tumours with different growth rates, and it is further supported by the findings of progression times, which vary with both DA and SR content. The reduced growth rate with increasing SR content may partly be explained by increasing response rates and response durations for patients who received endocrine therapy. However, it seems likely that the SR content also reflects basic growth rate, since the proliferative rate, estimated by the thymidine labelling index, TLI, increases with decreasing SR and increasing DA (Meyer et al., 1986; Adami et al., 1985) and since the TLI is related to prognosis (Strauss et al., 1982) .
Patients with different stages of primary breast cancer are supposed to have tumours of different ages (Kamby et al., 1987) . Thus, stage of disease may be regarded as a chronological prognostic factor. Higher grades of anaplasia were more common in patients with stage II than stage I tumours. The influence of DA on prognosis may, therefore, also contain an element of tumour chronology. In contrast, since the SR content of the primary tumours was not associated with stage, the impact on survival of SR content does not seem to include differences in tumour age.
In recurrent breast cancer, the prognosis (i.e., the SAR) is among other factors influenced by the anatomical location and the number of recurrences (Vincent et al., 1986; Hietanen et al., 1986) . Since SAR in the present study was related to both DA and SR content of the primary tumour, it seems plausible that the influence on prognosis of these factors may be mediated through variations in the pattern of dissemination. However, since the number of anatomical regions with metastases was unassociated with both DA and SR content, it is unlikely that the effect on SAR is mediated through differences in the extent of dissemination. When analyzing the distribution of metastases, however, it was found that initial signs of poor prognosis also reflect the appearance of metastases in organs where lethality would be greater (i.e., brain, liver, and lung), and that receptor positive patients had a propensity for developing bone metastases compared to receptor negative patients. The increased incidence of liver metastases among patients with low differentiated tumours confirms the findings of Bunting et al. (1976) and Coleman & Rubens (1987) . Moreover, the literature shows that ER negative tumours preferentially metastasize to viscera (Campbell et al., 1981; Qazi et al., 1984; Singhakowinta et al., 1980; Samaan et al., 1981) , while ER positive tumours metastasize to bone (Campbell et al., 1981; Qazi et al., 1984; Singhakowinta et al., 1980; Walt et al., 1976 , Stewart et al., 1981 Clark et al., 1987; Williams et al., 1987) .
The different metastatic patterns of tumours with varying degrees of tumour differentiation and SR content support experimental data concerning clonal evolution and metastasis. According to these, the appearance of clinical metastases is the end result of a process, where selection, adaptation, and growth of tumour cells in various organs lead to progressive heterogeneity between both the primary tumour and the metastases, and between metastases in various organs (Nowell, 1976; Poste & Fidler, 1980) . Thus, the propensity of ER positive tumours to recur in the contralateral breast may suggest a growth lead of these tumours compared to ER negative tumours. Moreover, as the hormonal microenvironment of the contralateral breast is expected to facilitate growth of ER rich tumour cells, tamoxifen treatment may reverse this. In accordance with this view, a reduced incidence of contralateral breast tumours was found in tamoxifen treated patients from the NATO trial (Cuzick & Baum, 1985) . Why SR rich tumours tend to recur more often in bone is not known. Since ER positive tumour cells are capable of inducing osteolysis in vitro (Valentin-Opran et al., 1985) , these cells may have a survival advantage in the bone system when compared to ER negative cells. In the present study, radiographic osteolysis was more often found in ER negative patients. Since endocrine therapy inhibits the growth of SR rich tumours, and since osteosclerosis may be an indicator of tumour cell response to endocrine therapy (Coombes et al., 1983) , the radiographic appearance of osteosclerotic bone metastases in SR positive patients and the appearance of osteolysis in SR negative patients are compatible with the present findings.
The inclusion of tamoxifen treated patients in the current study probably does not introduce bias, because randomization resulted in equal SR contents in tumours of treated and untreated patients, Because of low number of receptor determined patients it was not possible to analyze the metastatic pattern in relation to both the type of adjuvant systemic treatment and SR status at the same time. We have, however, previously reported (Kamby et al., 1988b ) that failures of adjuvant tamoxifen treatment often involve appearance of lung metastases. This is in agreement with the present results, since ER negative tumours disseminate to lung more often than do ER positive tumours.
In conclusion, it is most likely that the influence on prognosis of tumour grade and SR content works through multiple 'mechanisms'. Of these, biological growth properties such as growth rate and metastatic pattern are probably of greatest importance. The acknowledgement of site specific differences in SR content has implications for rational application of endocrine therapy. Thus, one should not regard patients as either receptor positive or negative, based on primary tumour determinations only. Instead, SR measurements should be performed on metastases in various locations before deciding on treatment.
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